$PIII

P3 Health Partners Inc. (PIII): Submission of Matters to a Vote of Security Holders

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Submission of Matters to a Vote of Security Holders. piii-20260609 0001832511 false 0001832511 2026-06-09 2026-06-09 0001832511 us-gaap:CommonClassAMember 2026-06-09 2026-06-09 0001832511 us-gaap:WarrantMember 2026-06-09 2026-06-09 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSU

Original reporting
Published Jun 9, 2026, 9:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 10, 2026, 10:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$PIII
Neutral
medium confidence
Mentioned
$PIII
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$PIIINeutralLow
01

Why it matters

Proposals 2–4 were approved, including Nasdaq Rule 5635(d) approval to issue up to 3,341,130 Class A shares upon exercise of outstanding warrants held by VBC Growth SPV 5, LLC.

02

Market read

The only potentially tradable item is the approved warrant-related share issuance authorization, which can influence dilution/warrant overhang expectations.

03

What to watch

Traders may focus on whether warrant holders are likely to exercise soon versus later, which is not quantified in the filing.

Relevance 6/10Novelty 4/10Timing: after-hours/filing update from June 9, 2026 annual meeting results

Background

The SEC 8-K reports matters submitted to a vote at P3 Health Partners’ 2026 annual meeting on June 9, 2026.

Company-level read

Ticker impact

$PIIINeutralMedium confidence
Context

P3 Health Partners reported 2026 annual meeting voting results, including approval to issue up to 3,341,130 shares on warrant exercise.

Expected impact

Likely limited near-term impact; any move would be driven by how traders price potential dilution from warrant exercises.

Evidence & confidence

The filing is a corporate governance/authorization update (not a new financing or deal), but it explicitly approves a defined share issuance amount tied to warrants.

Market effects

Minimal; this is company-specific governance and warrant-share issuance mechanics.

None indicated.

None indicated.

Counterpoint

Even with approval, actual warrant exercise timing/likelihood may be low, so dilution may not materialize soon.

Key entities

  • P3 Health Partners Inc.

    Company filing the 8-K; held annual meeting and reported voting outcomes.

  • VBC Growth SPV 5, LLC

    Holds outstanding Class A common stock warrants whose exercise could trigger issuance of up to 3,341,130 shares.

  • BDO USA, P.C.

    Ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2026.

Related articles

$PIIIMedAI 9/10

P3 Health Partners (PIII) Q2 2026 Earnings Call Transcript

P3 Health Partners (PIII) reported Q2 2026 adjusted EBITDA of $54.4 million versus a prior-year loss, on total revenue of $386.4 million (+9% YoY). At-risk membership fell 10% to 105,000. Net income was $15.7 million. The company raised full-year 2026 guidance to adjusted EBITDA of $80 million to $110 million and revenue of $1.5 billion to $1.6 billion.

$PIIIHigh

P3 Health Partners Inc. (PIII): Results of Operations and Financial Condition

P3 Health Partners Inc. (PIII) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 P3 Health Partners Announces Second Quarter 2026 Results Raises Full-Year 2026 Adjusted EBITDA Guidance Management to Host Conference Call and Webcast August 10, 2026 at 4:30 PM ET HENDERSON, NV—August 10, 2026—P3 Health Partners Inc. (“P3” or the “Company”) (NASDAQ:

$PIIIMedAI 8/10

Short Interest in P3 Health Partners Inc. (NASDAQ:PIII) Rises By 293.3%

P3 Health Partners (NASDAQ:PIII) reported short interest of 283,541 shares as of May 15, up 293.3% from 72,094 on April 30; about 4.8% of shares are sold short, with a days-to-cover ratio near 0.0. The stock fell 26% on Friday to $12.18. UBS and Lake Street set $14 targets; TD Cowen reiterated hold. The company reported Q1 EPS of $0.32 on revenue of $386.39M.

$QTTBMedAI 9/10

Top Biotech Gainers: QTTB Has A Good Hair Day, GH Wins ACS Recommendation, Ebola Lifts SNGX, NNVX

Biotech stocks rose on varied catalysts. Q32 Bio (QTTB) jumped 85% after a $55M private placement at $8.00/share; topline SIGNAL-AA Phase 2a Part B data are expected mid-2026. Soligenix (SNGX) gained 69% as it evaluates ThermoVax for Bundibugyo Ebola. Guardant (GH) rose 6% after ACS added its Shield blood test to updated colorectal screening guidelines; Q1 revenue was $301.7M (+48%).

$ORCLHighAI 8/10

Oracle Hits Workers With Second Wave of 6 AM Emails as Restructuring Bill Climbs to $2.8B

Oracle sent a second wave of 6 AM termination emails to employees globally, coinciding with a disclosed $2.8B restructuring cost, up from $2.1B. The company reported record Q1 FY27 revenue of $19.3B, up 30% YoY, with cloud revenues rising 62%. Oracle's restructuring plan continues, with estimates suggesting 7,000-10,000 jobs cut, including significant reductions in India. The company's capital expenditures totaled $28.5B in Q1, with free cash flow at -$5.4B.